

Exhibit A

NY2 - 1386431.1

EXHIBIT A
MARKED UP COPY OF CLAIMS AMENDED ON JANUARY 5, 2003
U.S. PATENT APPLICATION NO. 09/509,283
ATTORNEY DOCKET NO. 7853-215

76. (Four times amended) A monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said 8F4 polypeptide:

- a) is an inducible T cell costimulatory molecule;
- b) occurs on two-signal-activated human T lymphocytes;
- c) exhibits a molecular weight of about 55 to 60 kilodaltons as determined by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE); and
- d) is a dimer of two peptide chains exhibiting molecular weights of about 27 kilodaltons and 29 kilodaltons, as measured by reducing SDS-PAGE,

wherein the human 8F4 polypeptide is recognized by the antibody deposited with the DSMZ and assigned accession no. DSM ACC2539;

wherein the monoclonal antibody, [when immobilized on a solid surface and] in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates proliferation of human T lymphocytes;

and wherein the monoclonal antibody inhibits costimulation of T lymphocytes by the human 8F4 polypeptide.

83. (Four times amended) A hybridoma that produces a monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said 8F4 polypeptide:

- a) is an inducible T cell costimulatory molecule;
- b) occurs on two-signal-activated human T lymphocytes;
- c) exhibits a molecular weight of about 55 to 60 kilodaltons as determined by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE); and
- d) is a dimer of two peptide chains exhibiting molecular weights of about 27 kilodaltons and 29 kilodaltons, as measured by reducing SDS-PAGE,

wherein the human 8F4 polypeptide is recognized by the antibody deposited with the DSMZ and assigned accession no. DSM ACC2539;

wherein the hybridoma produces a monoclonal antibody,

wherein the monoclonal antibody, [when immobilized on a solid surface and] in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates proliferation of human T lymphocytes;

and wherein the monoclonal antibody inhibits costimulation of T lymphocytes by the human 8F4 polypeptide.

86. (Four times amended) A pharmaceutical composition comprising a monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said 8F4 polypeptide:

- a) is an inducible T cell costimulatory molecule;
- b) occurs on two-signal-activated human T lymphocytes;
- c) exhibits a molecular weight of about 55 to 60 kilodaltons as determined by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE); and
- d) is a dimer of two peptide chains exhibiting molecular weights of about 27 kilodaltons and 29 kilodaltons, as measured by reducing SDS-PAGE,

wherein the human 8F4 polypeptide is recognized by the antibody deposited with the DSMZ and assigned accession no. DSM ACC2539;

and wherein the pharmaceutical composition comprises a monoclonal antibody;

wherein the monoclonal antibody, [when immobilized on a solid surface and] in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates proliferation of human T lymphocytes;

and wherein the monoclonal antibody inhibits costimulation of T lymphocytes by the human 8F4 polypeptide.

99. (Amended) A hybridoma [Hybridoma] cell line deposited with the DSMZ and assigned accession no. DSM ACC2539.